Literature DB >> 23574311

T cell depletion in paediatric stem cell transplantation.

C Booth1, P Veys.   

Abstract

Haematopoietic stem cell transplantation (HSCT) can be a curative procedure for a growing number of paediatric diseases, but as the indications for HSCT grow, so does the need to find suitable stem cell donors. When the preferred option of a genoidentical sibling donor is not available alternative donors, including unrelated adult or umbilical cord blood donors, or haploidentical related donors may be considered. Outcome following alternative donor HSCT has improved over the past 20 years but graft-versus-host disease (GvHD) remains a significant obstacle. T cell depletion (TCD) for non-genoidentical grafts aims to reduce the morbidity and mortality associated with GvHD, but this intervention has not led directly to improved survival due to delayed immune reconstitution and increased infections, graft rejection and increased rates of disease relapse. Limited data from the paediatric population, however, suggest some encouraging results for children undergoing haploidentical HSCT: a move from positive selection of CD34(+) haematopoietic stem cells towards negative depletion of specific cell subsets in order to retain useful accessory cells within the graft appears to enhance immune reconstitution and improve disease-free survival. Here we review recent paediatric outcome data for T cell-depleted HSCT, explore the role of serotherapy in conditioning regimens and look at future possibilities to improve outcome, including novel allodepletion techniques, suicide gene therapy and pathogen-specific immunotherapy.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574311      PMCID: PMC3628317          DOI: 10.1111/cei.12004

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  75 in total

1.  Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.

Authors:  Katia Perruccio; Fabiana Topini; Antonella Tosti; Alessandra Carotti; Teresa Aloisi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood Cells Mol Dis       Date:  2007-11-05       Impact factor: 3.039

Review 2.  Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.

Authors:  F Aversa
Journal:  Bone Marrow Transplant       Date:  2008-01-07       Impact factor: 5.483

3.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

Review 4.  Pharmacokinetics of alemtuzumab and the relevance in clinical practice.

Authors:  Thomas Elter; Istvan Molnar; Jens Kuhlmann; Michael Hallek; Clemens Wendtner
Journal:  Leuk Lymphoma       Date:  2008-12

5.  T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors.

Authors:  Patrizia Comoli; Marco W Schilham; Sabrina Basso; Tamara van Vreeswijk; Maria Ester Bernardo; Rita Maccario; Maarten J D van Tol; Franco Locatelli; Louise A Veltrop-Duits
Journal:  J Immunother       Date:  2008 Jul-Aug       Impact factor: 4.456

6.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

7.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Authors:  Tanzina Haque; Gwen M Wilkie; Marie M Jones; Craig D Higgins; Gillian Urquhart; Phoebe Wingate; David Burns; Karen McAulay; Marc Turner; Christopher Bellamy; Peter L Amlot; Deirdre Kelly; Alastair MacGilchrist; Maher K Gandhi; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

8.  T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.

Authors:  P Comoli; S Basso; M Labirio; F Baldanti; R Maccario; F Locatelli
Journal:  Blood Cells Mol Dis       Date:  2007-09-29       Impact factor: 3.039

9.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Authors:  Wolfgang A Bethge; Christoph Faul; Martin Bornhäuser; Gernot Stuhler; Dietrich W Beelen; Peter Lang; Matthias Stelljes; Wichard Vogel; Matthias Hägele; Rupert Handgretinger; Lothar Kanz
Journal:  Blood Cells Mol Dis       Date:  2007-09-14       Impact factor: 3.039

10.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

View more
  11 in total

1.  Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings.

Authors:  Susanna S Park; Gerhard Bauer; Mehrdad Abedi; Suzanne Pontow; Athanasios Panorgias; Ravi Jonnal; Robert J Zawadzki; John S Werner; Jan Nolta
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

Review 2.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis.

Authors:  R Admiraal; R Chiesa; C A Lindemans; S Nierkens; M B Bierings; A B Versluijs; P Hiwarkar; J M Furtado Silva; P Veys; J J Boelens
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

4.  Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Authors:  T Cluzeau; J Lambert; N Raus; K Dessaux; L Absi; F Delbos; A Devys; M De Matteis; V Dubois; M Filloux; M Fort; F Hau; I Jollet; M Labalette; D Masson; B Mercier; B Pedron; P Perrier; C Picard; F Quainon; A Ramounau-Pigot; V Renac; P Van Endert; D Charron; R Peffault de la Tour; J L Taupin; P Loiseau
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 5.  Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

Authors:  Coco de Koning; Rick Admiraal; Stefan Nierkens; Jaap Jan Boelens
Journal:  Stem Cell Investig       Date:  2017-05-16

6.  Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.

Authors:  Carmen Gómez-Santos; Marta González-Vicent; Blanca Molina; Natalia Deltoro; Blanca Herrero; Julia Ruiz; Antonio Pérez-Martínez; Miguel A Diaz
Journal:  World J Pediatr       Date:  2021-09-30       Impact factor: 9.186

7.  Predicting CD4 T-Cell Reconstitution Following Pediatric Hematopoietic Stem Cell Transplantation.

Authors:  R L Hoare; P Veys; N Klein; R Callard; J F Standing
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

8.  Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.

Authors:  Rick Admiraal; Cornelia M Jol-van der Zijde; Juliana M Furtado Silva; Catherijne A J Knibbe; Arjan C Lankester; Jaap Jan Boelens; Goeff Hale; Aniekan Etuk; Melanie Wilson; Stuart Adams; Paul Veys; Charlotte van Kesteren; Robbert G M Bredius
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 9.  Umbilical cord blood: The promise and the uncertainty.

Authors:  Tamila L Kindwall-Keller; Karen K Ballen
Journal:  Stem Cells Transl Med       Date:  2020-07-03       Impact factor: 6.940

10.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.